BIAFINEACT Emuls pour application cutanée T/139,5g

Triethanolamine ....................................................................................................................................... 0,670 g

For 100 g of emulsion for cutaneous application.

Excipients with known effect: propylene glycol, potassium sorbate, sodium methyl parahydroxybenzoate (E 219), sodium propyl parahydroxybenzoate (E 217), Yerbatone fragrance.

• Treatment of superficial and limited-extent burns, including localized sunburn.
• Non-infected cutaneous wounds.

Cutaneous use.

• Treatment of superficial and limited-extent burns, including localized sunburn: apply in a thick layer until the skin is saturated. Massage lightly to penetrate. Renew 2 to 4 times per day.
• Non-infected cutaneous wounds: after cleaning the wound, apply in a thick layer extending well beyond the edge of the lesion and renew applications so as to always maintain an excess of emulsion over the lesion.

• Hypersensitivity to the active substance or to any of the excipients listed in section Composition.
• Haemorrhagic wound.
• Infected lesion.

Special warnings

For superficial burns or non-infected cutaneous wounds, the management will depend on the extent and location of the lesion, the patient's age and history, associated lesions and the etiology.

Precautions for use

This medicine is not a sunscreen.

This medicine must not be used as a skincare cream on healthy skin.

Do not apply near the eyes.

This medicine contains 38 mg of propylene glycol per 1,65 g dose and may cause skin irritation.

Do not use this medicine in babies younger than 4 weeks with open wounds or large areas of damaged or injured skin (burns).

This medicine contains potassium sorbate and may cause local skin reactions (for example: eczema).

This medicine contains sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate and may cause allergic reactions (possibly delayed).

This medicine contains a fragrance (Yerbatone fragrance) containing the following substances: 3-Methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, benzyl benzoate, citral, citronellol, d-limonene, eugenol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol and linalool. These substances may cause allergic reactions.

No interaction studies have been performed.

Pregnancy

There are no data in pregnant women. However, no effect is expected in pregnant women, nor on the foetus.

Breast-feeding

There are no data in breastfeeding women. However, no effect is expected in breastfeeding women, nor on the breastfed infant.

There are no data on the passage of trolamine or its metabolites into milk.

Undesirable effects are classified according to their frequency of occurrence, as follows: uncommon (≥ 1/1 000, < 1/100), rare (≥ 1/10 000, < 1/1 000) and very rare (< 1/10 000).

General disorders and administration site conditions:

• Uncommon: moderate, transient tingling-type pain after application.
• Rare: contact allergy.
• Very rare: contact eczema requiring immediate discontinuation of treatment.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres - Website: https://signalement.social-sante.gouv.fr/.

No cases of overdose have been reported.

Pharmacotherapeutic class: SKIN PROTECTANT, ATC code: D03AX12 (D. Dermatology).

Trolamine, combined with fatty acids such as stearic acid, acts as an emulsifier. After cutaneous application, it develops occlusive and moisturising properties, increases the recruitment of macrophages at the wound site, and promotes healing in the dermis and the formation of granulation tissue.

The effects of this medicine are limited to the superficial layers of the epidermis and promote hydration. No systemic effect is expected.

The tests in vitro for mutagenicity and chromosomal aberrations conducted with trolamine were negative.

The results of carcinogenicity studies in rodents are equivocal. There are no data in humans.

Trolamine proved to be embryotoxic in a reproduction study in chickens. There are no data in humans.

3 years.

Do not freeze.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.